A 12-Week Randomized, Double-Blinded Study to Evaluate the Effects of Daily Oral Doses of BMS-741672 in Drug-Naive Type 2 Diabetic Patients
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs BMS 741672 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 29 Jun 2010 Actual patient number (58) added as reported by ClinicalTrials.gov.
- 29 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.